Patients in Scotland suffering from inflammatory conditions including rheumatoid arthritis (RA), Crohn's Disease (CD), ulcerative colitis (UC), and psoriasis will now have access to a new wave of biological medicines. Remsima® (infliximab) is a new biosimilar medicine which has the potential to bring significant savings to the NHS without compromising patient care. Patient access follows a review of Remsima by the SMC, which has accepted Remsima for restricted use in line with SMC and Health Improvement Scotland (HIS) advice for the originator medicine Remicade® (infliximab), in RA, UC (adults and paediatric), CD (adults and paediatric), psoriasis and psoriatic arthritis.
